Certain safety issues, such as infection-related (Liu et al., 2017), renal-related AEs (Menne et al., 2019), and diabetic ketoacidosis (Liu et al., 2020), have been raised with the extensive clinical application of SGLT2 inhibitors. This evidence concerns the gene SLC5A2 and diabetic ketoacidosis.